Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2022
Event: Entry into a Material Definitive Agreement and creation of a direct financial obligation.
Key Financial Metrics and Transaction Details
This filing reports a specific financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow).
- Instrument: 8% Convertible Promissory Note.
- Principal Amount: $63,750.
- Net Proceeds: $60,000 (intended for general working capital).
- Transaction Costs: $3,750 paid to the lender for legal fees and due diligence.
- Interest Rate: 8% per annum (payable in cash or shares upon maturity/acceleration).
- Maturity Date: May 12, 2023.
- Counterparty: 1800 Diagonal Lending LLC.
Material Changes and Terms
The primary material change is the incurrence of new debt with significant conversion and default provisions:
- Conversion Terms: The note is convertible into common stock at the option of the lender after 180 days. The conversion price is set at 65% of the "Market Price" (a 35% discount), calculated as the average of the lowest three trading prices over the ten trading days prior to conversion.
- Conversion Cap: The lender is restricted from converting if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
- Prepayment Penalties: Prepayment is allowed but subject to escalating premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment within the first 180 days.
- Default Provisions: Upon certain events of default, the outstanding principal and accrued interest increase to 150% (the "Default Amount").
- Penalty for Delay: A penalty of $1,000 per day applies if shares are not delivered within three business days of a conversion notice (unless caused by a third party).
Guidance, Risks, and Contingencies
Management Commentary: The Company intends to use the net proceeds for general working capital purposes. The transaction closed on May 16, 2022.
Risks and Contingencies:
- Dilution Risk: The 35% discount on the conversion price and the potential for interest to be paid in shares may result in significant dilution to existing shareholders.
- Liquidity Risk: The Company is restricted from selling substantially all assets without lender consent, which could limit strategic flexibility.
- Default Risk: The 150% default penalty significantly increases the liability in the event of insolvency, bankruptcy, or failure to maintain SEC reporting requirements.
- Listing Risk: Failure to maintain listing on an OTC market or equivalent exchange constitutes an event of default.
Investor Verification Checklist
- Verify the current trading price of Propanc Biopharma common stock to assess the potential dilution impact of the 35% discount conversion rate.
- Confirm the Company's ability to meet the $63,750 principal obligation plus 8% interest by the May 12, 2023 maturity date.
- Review the Company's cash position to ensure it can cover the escalating prepayment penalties if early repayment is considered.
- Check for any subsequent filings regarding the issuance of shares upon conversion or any events of default.
- Verify the Company's continued compliance with SEC reporting requirements to avoid triggering the default clause.